Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Context Therapeutics Inc. (NASDAQ: CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context ...

Mersana Therapeutics Inc. (NASDAQ: MRSN) is one of the best penny stocks under $1 to buy now. Earlier in June, Mersana Therapeutics presented additional positive interim Phase 1 clinical data for ...

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

A different study presented at the 2025 ASCO Annual Meeting showed that one specific diet may benefit people with colon ...

The Food Patrol is focusing on one bakery with many issues. Police and lawyers are getting involved because maggots were ...

In this video, Sham Mailankody, MBBS, discusses results from a first-in-human study of JNJ-5322, a next-generation trispecific antibody for treatment of patients with relapsed or refractory multiple ...

"Outside of metastatic castrate-resistant prostate cancer, both NCCN and ASCO do note that an osteoclast inhibitor (at ...

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

Nearly one-third of patients with pancreatic cancer missed germline testing, with the disparities tied to race, insurance, and care setting.

ASCO convened a panel of experts to update the clinical guidelines for fertility preservation in men, women, and adolescents with cancer.

A panelist discusses how ASCO 2025's most important breakthrough was the oral decitabine plus venetoclax combination, ...